Search results
Volta Medical Presents Results From First Transatlantic Randomized Controlled Trial Comparing...
NewMediaWire via Yahoo Finance· 1 day agoTAILORED-AF trial findings demonstrated superiority in freedom from atrial fibrillation (AF) with or...
Ozempic, Wegovy to be tested as alcohol-related liver disease therapies
Becker’s Hospital Review· 7 days agoNovo Nordisk is investigating the potential of Ozempic, Wegovy's active ingredient and two other drug candidates as treatments for alcohol-related liver disease. The phase 2 trial will see how ...
Breast Cancer Risk After Bariatric Surgery and Influence of Insulin Levels
Journal of the American Medical Association· 7 days agoThis nonrandomized controlled trial evaluates the association between bariatric surgery and breast cancer incidence and whether this association varies by baseline insulin level.
Nanopharmaceutics and Northwestern University Announce Initiation of Phase I Adaptive Dose...
WJTV Jackson· 7 days agoThe primary objective of this phase 1 study will be to determine the recommended phase 2 dose (RP2D) for Triapine® in combination with temozolomide (TMZ).
BioCorRx Reports Business Update for the First Quarter of 2024
NewMediaWire via Yahoo Finance· 5 days agoANAHEIM, CA - (NewMediaWire) - May 16, 2024 - BioCorRx Inc. (OTCQB: BICX) (the "Company"), a...
NIH Reports Benign Nail Condition Linked to Rare Syndrome that Greatly Increases Cancer Risk
Sierra Sun Times· 3 days agoNIH researchers suggest conducting nail evaluation of affected patients and at-risk family members....
Spago Nanomedical Provides an Update on Tumorad-01 - Trial Proceeds as Planned
Morningstar· 2 days agoLUND, SWEDEN / ACCESSWIRE / May 20, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that both of the clinical sites in the phase I/IIa study Tumorad ...
GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update
NewMediaWire via Yahoo Finance· 7 days agoPresented data on GEO-CM04S1 at World Vaccine Congress, delineating the unique immune system driven...
Oak Hill Bio and Chiesi Group Announce First Patient Enrolled in the Resumed Phase 2b Clinical Study...
The Martinsburg Journal· 4 days agoDesign of the multi-center study is based on Phase 2a clinical data, which showed a decrease in the occurrence of severe bronchopulmonary dysplasia (BPD), a condition for which there are no ...
Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration...
Morningstar· 6 days agoBristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma 95.7% of patients responded to Breyanzi in the TRANSCEND FL trial Breyanzi provided sustained clinical